Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series.
The newly synthesized 14-alkoxymetopon derivatives, 14-methoxymetopon, 14-ethoxymetopon, 14-methoxy-5-methyl-morphinone, exhibit high affinity for the naloxone binding sites in rat brain. A substantial decrease in affinity was observed, in the presence of NaCl indicating a high degree of agonist activity. All three 14-alkoxymetopon derivatives displayed high affinity for [3H][D-Ala2,(Me)Phe4,Gly-ol5]enkephalin ([3H]DAMGO) binding sites, much less potency toward delta sites and were the least effective at kappa sites. Isolated tissue studies using the guinea pig ileum preparation confirmed their high agonist potency. Following administration the new compounds produced naloxone reversible antinociceptive effects and were 130-300 times more potent than morphine in the acetic acid induced abdominal constriction model in the mouse, and the hot plate and tail flick tests in the rat. The compounds also produced dose-dependent muscle rigidity, and potentiated barbiturate-induced narcosis. The in vivo apparent pA2 values for naloxone against 14-ethoxymetopon and morphine were similar in analgesia, suggesting an interaction with the same (mu) receptor site. The dependence liability of 14-alkoxymetopon derivatives in the withdrawal jumping test was less pronounced than that of morphine in either rats or mice, similar to tolerance to the their analgesic action. It is concluded that the 14-alkoxymetopon derivatives studied are selective and potent agonists at mu opioid receptors, with reduced dependence liability.
Fürst
Z
Z
Biological Research Center Szeged, Hungary.
Búzás
B
B
Friedmann
T
T
Schmidhammer
H
H
Borsodi
A
A
D000700:Analgesics / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001665:Binding Sites; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D009022:Morphine Derivatives / Q000378:metabolism / Q000494:pharmacology*; D009270:Naloxone / Q000037:antagonists & inhibitors; D010111:Oxymorphone / Q000031:analogs & derivatives; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000187:drug effects* / Q000378:metabolism; D013045:Species Specificity; D019966:Substance-Related Disorders
D000700:Analgesics; D004745:Enkephalins; D009022:Morphine Derivatives; D011957:Receptors, Opioid; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C081949:14-methoxymetopon; C081950:14-ethoxymetopon; C081951:14-methoxy-5-methylmorphinone; D009270:Naloxone; D010111:Oxymorphone